Merck’s Peter S. Kim to Deliver Keynote Address at BIO CEO and Investor Conference
WASHINGTON, D.C. (January 23, 2006) -- Peter S. Kim, President of Merck Research Laboratories, will be delivering the luncheon keynote address at the 8th annual CEO and Investor Conference organized by the Biotechnology Industry Organization (BIO) on February 14th, 2006 at the Waldorf=Astoria Hotel in New York City. Dr. Kim has been leading the research effort at Merck since 2003 overseeing 10,000 employees in the discovery of new drugs. The BIO CEO and Investor Conference is the leading industry-sponsored gathering of investors and biotechnology companies to discuss future trends and opportunities within the life sciences industry. Complimentary registration is open to qualified investors and members of the media at http://www.ceo.bio.org.
Dr. Kim’s presentation entitled “Creating New Hope through Research” will discuss the advances made and future prospects of new approaches to drug discovery productivity and the promise of advances in vaccines, personalized medicines, genomics, proteomics and new technologies.
Dr. Kim is President, Merck Research Laboratories (MRL). He is an elected member of the National Academy of Sciences, and its Institute of Medicine. His former affiliations include: Executive Vice President, Research and Development, MRL; Associate Head, Department of Biology, M.I.T; Investigator, Howard Hughes Medical Institute; Professor of Biology, M.I.T.; Member, Whitehead Institute for Biomedical Research; and Whitehead Fellow, Whitehead Institute for Biomedical Research.
Dr. Kim received his Ph.D. in biochemistry at Stanford University and an A.B. in chemistry at Cornell University. Dr. Kim currently is a member of the Board of Directors, Fox Chase Cancer Center and the Whitehead Institute for Biomedical Research; and is a member of the oversight committee, Division on Earth and Life Studies, The National Academies; and a council member of the Institute of Medicine, National Academy of Sciences.
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and 31 other nations. BIO members are involved in the research and development of healthcare, agricultural, industrial and environmental biotechnology products.